24 March 2025
Te Kāhui Mātai Arotamariki o Aotearoa | The Paediatric Society of New Zealand has submitted feedback in support of PHARMAC’s proposal to fund Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes.
While Ryzodeg is primarily intended for adults with type 2 diabetes, PSNZ highlighted that some children and young people with type 1 diabetes may also benefit. Simplified insulin regimens can support better adherence, improved glucose control, and quality of life for tamariki and rangatahi—especially those facing challenges related to complex treatment plans.
The Society emphasised the importance of offering a wider range of insulin options to support flexible, individualised care. Greater treatment choice can also help address inequities, particularly for young people navigating social, developmental, or resource-related barriers to effective diabetes management.
PSNZ encourages PHARMAC to consider how increasing access to diverse insulin treatments can reduce preventable disparities and support long-term health outcomes for children and young people living with diabetes.
Read the full submission below 👇